Home page

CARDIOPROGRESS
Foundation for the advancement of cardiology

Knowledge, observation, action

  РУС

Feedback

RU EN
  •  About Foundation 
  •  Scientific news 
  •   Events  
  •   Projects  
  •   Guidelines  
  •   Trials  
  •   Editorial activity  
  •   Archive  
  • Главная
  •   Events  
  • Russian cardio events

Russian cardio events

 


Russian scientific events 2024



Russian scientific events 2022



Russian scientific events 2021



Russian scientific events 2020



Russian scientific events 2016



Russian scientific events 2015



Russian scientific events 2013


Scientific news

  • Blood Pressure Variability Linked to Mortality in Patients With ANCA-Associated Vasculitis Among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis undergoing maintenance therapy, greater visit-to-visit systolic blood pressure variability (SBPV) was independently associated with an increased risk for all-cause mortality.

  • Morphine Underused for End-of-Life Dyspnea in the Emergency Department Compared with Inpatient Care Among 250 patients presenting to the emergency department (ED) with dyspnea at the end of life, 15.2% received morphine in the ED, whereas 68% received it during subsequent inpatient care. Patients with lung cancer or a do-not-resuscitate order were more likely to receive morphine in the ED, but its use was not associated with reduced survival.

  • Present state and future of screening for atrial fibrillation: a state-of-the-art review Atrial fibrillation is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains undiagnosed. Screening has been proposed to identify asymptomatic AF and initiate preventive treatment, but evidence for reduction in hard clinical endpoints such as stroke and heart failure remains inconclusive.

  • Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials Acute decompensated heart failure with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties.

  • Cardiovascular Benefits of Semaglutide in SELECT Trial Not Fully Explained by Weight Loss and Other Improvements In adults with obesity and established cardiovascular disease (CVD), semaglutide was associated with improvements in several risk factors. However, those changes only accounted for part of the reduced risk for major adverse cardiovascular events (MACE) noted in the SELECT trial.

Partners

  • The Department of Health in Moscow
  • The State Committee on Health
  • Silicea-Poligraf, publishing house

Video resource

Channel "Cardioprogress"

Follow us

Top.Mail.Ru

© 2012-2018 Foundation for the advancement of cardiology «Cardioprogress»